Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 16/20 | 0.69 |
| ▸ | FGFR1 | P11362 | 9/20 | 0.69 |
| ▸ | KDR | P35968 | 8/20 | 0.69 |
| ▸ | INSR | P06213 | 4/20 | 0.54 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.49 |
| ▸ | AURKA | O14965 | 2/20 | 0.48 |
| ▸ | PLK4 | O00444 | 2/20 | 0.48 |
| ▸ | PAK4 | O96013 | 2/20 | 0.48 |
| ▸ | JAK2 | O60674 | 1/20 | 0.48 |
| ▸ | STK10 | O94804 | 1/20 | 0.48 |
| ▸ | RET | P07949 | 1/20 | 0.48 |
| ▸ | FER | P16591 | 1/20 | 0.48 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.48 |
| ▸ | JAK1 | P23458 | 1/20 | 0.48 |
| ▸ | TYK2 | P29597 | 1/20 | 0.48 |
| ▸ | FLT3 | P36888 | 1/20 | 0.48 |
| ▸ | STAT3 | P40763 | 1/20 | 0.48 |
| ▸ | STAT5A | P42229 | 1/20 | 0.48 |
| ▸ | JAK3 | P52333 | 1/20 | 0.48 |
| ▸ | CDK3 | Q00526 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3864859 | 0.90 | IGF1R (0.79) | IGF1RFGFR1KDRINSRNTRK1 | |
| SCHEMBL3861790 | 0.89 | IGF1R (0.65) | IGF1RFGFR1KDRINSRNTRK1 | |
| SCHEMBL2122601 | 0.88 | IGF1R (0.67) | IGF1RFGFR1KDRINSRNTRK1 | |
| SCHEMBL2121059 | 0.88 | IGF1R (0.81) | IGF1RFGFR1KDRINSR | |
| SCHEMBL4034359 | 0.87 | IGF1R (0.66) | IGF1RFGFR1KDRINSR | |
| SCHEMBL2122642 | 0.86 | IGF1R (0.72) | IGF1RFGFR1KDRINSR | |
| SCHEMBL4032551 | 0.84 | IGF1R (0.79) | IGF1RFGFR1KDRINSRNTRK1 | |
| SCHEMBL4037067 | 0.83 | IGF1R (0.69) | IGF1RFGFR1KDRINSR | |
| SCHEMBL2121130 | 0.82 | IGF1R (1.00) | IGF1RFGFR1KDRINSRNTRK1 | |
| SCHEMBL4035278 | 0.81 | IGF1R (0.83) | IGF1RFGFR1KDRINSRNTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7521453-B2 | e.g. 5-Bromo-2-(3-methylisoxazol-5-ylmethylamino)-4-(5-cyclopropyl- 1H-pyrazol-3-ylamino)pyrimidine; anticarcinogenic, antitumor agents; breast, prostate, colon cancer | ASTRAZENECA AB (SE) | 2009-04-21 | — | — | US | claimed |
| EP-1456182-B1 | PYRIMIDINE DERIVATIVES AS MODULATORS OF INSULINE-LIKE GROWTH FACTOR-1 RECEPTOR (IGF-I) | ASTRAZENECA AB (SE) | 2009-03-11 | — | — | EP | claimed |
| US-20050054638-A1 | Pyrimidine derivatives as modulators of insulin-like growth factor-1 receptor (igf-i) | ASTRAZENECA AB | 2005-03-10 | — | — | US | claimed |
| EP-1456182-A1 | PYRIMIDINE DERIVATIVES AS MODULATORS OF INSULINE-LIKE GROWTH FACTOR-1 RECEPTOR (IGF-I) | AstraZeneca AB (SE) | 2004-09-15 | — | — | EP | claimed |
| WO-2003048133-A1 | PYRIMIDINE DERIVATIVES AS MODULATORS OF INSULINE-LIKE GROWTH FACTOR-1 RECEPTOR (IGF-I) | ASTRAZENECA AB (SE) | 2003-06-12 | — | — | WO | claimed |
| EP-1456182-B1 | PYRIMIDINE DERIVATIVES AS MODULATORS OF INSULINE-LIKE GROWTH FACTOR-1 RECEPTOR (IGF-I) | ASTRAZENECA AB (SE) | 2009-03-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054638-A1 | Pyrimidine derivatives as modulators of insulin-like growth factor-1 receptor (igf-i) | IGF1R, IGFBP1, INSR | IGF1R 1/4885FGFR1 15/4885KDR 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.